The efficacy of endoscopic therapy for pancreas divisum: a meta-analysis

Lamprinos Michailidis, Bilal Aslam, Alla Grigorian, Houssam Mardini
University of Kentucky College of Medicine, USA

Abstract

Background The purpose of this study was to perform a meta-analysis assessing the efficacy and predictors of success of endoscopic therapy in the management of patients with pancreas divisum.

Methods An electronic database search (PubMed and ScienceDirect) was performed for relevant studies. Studies were selected based on predefined criteria and data were extracted on patient population, follow up, endotherapy methods, success rates and complication rates. A random-effect model was used to pool the effect size across studies. Heterogeneity testing and publication bias assessment were performed. Multivariate regression analysis was performed to identify predictors of successful endoscopic therapy.

Results Of 381 articles reviewed, 23 studies with 874 patients met the inclusion criteria. All were case series with suboptimal quality. Endoscopic therapy included minor papilla sphincterotomy, minor papilla sphincteroplasty and dorsal duct stenting. Mean follow-up duration was 37 months. The rate of “improvement” as defined by authors after endoscopic therapy varied significantly across studies, ranging from 31-96%: 589/874 patients were reported to have improved, corresponding to a pooled efficacy rate of 67.5% (95% confidence interval [CI] 0.610-0.734; P=0.0001). The pooled rate of pancreatitis after endoscopic retrograde cholangiopancreatography was 10.1% (95%CI 0.084-0.124; 2-sided P=0.0001). On subgroup analysis, patients with recurrent acute pancreatitis had better endoscopic outcomes (pooled efficacy rate 76%, 95%CI 0.712-0.803, P=0.0001). Dorsal duct stenting and longer follow up were the only parameters predictive of successful endotherapy. Significant heterogeneity was observed within and across studies.

Conclusions Endoscopic efficacy in pancreas divisum is estimated at 67.5%. Available studies are of poor quality with significant heterogeneity. Comparative studies with rigorous methodology are needed.

Keywords Pancreas divisum, endoscopic therapy, minor papilla sphincterotomy, meta-analysis, systematic review, recurrent acute pancreatitis, chronic pancreatitis

Ann Gastroenterol 2017; 30 (3): 550-558

Introduction

It is estimated that 5-10% of people are born with pancreas divisum (PDiv) [1,2], which has been implicated in the pathogenesis of acute, recurrent and chronic pancreatitis, as well as pancreatic type abdominal pain. Ductal obstruction and/or minor papilla stenosis have been proposed as responsible for the clinical presentation [3], which is categorized into 3 groups: recurrent acute pancreatitis (RAP) episodes, chronic pancreatitis (CP) and pancreatic-type pain (PP) with no objective findings of pancreatitis [3-5]. Therefore, dorsal ductal decompression at the level of the minor papilla has been the mainstay of surgical and/or endoscopic therapies of PDiv. Endoscopically, the most frequently employed methods are minor papilla sphincterotomy, minor papilla sphincteroplasty, and dorsal duct stenting alone or in combination with the aforementioned. While these interventions are widely accepted and performed in patients with clinically evident PDiv, most of the evidence available comes from small, uncontrolled, retrospective studies. In addition, efficacy rates are widely variable and the predictors of successful endoscopic therapy remain unclear. We sought to perform a meta-analysis of studies...
to estimate the efficacy of endoscopic therapy and identify potential predictors of successful endoscopic intervention in patients with PDiv by subgroup and meta-regression analysis.

Materials and methods

Design, analysis, and reporting were performed according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement and guidelines [6].

Literature search

A systematic literature search was performed to identify all reports of endoscopic therapy attempts in patients with PDiv through January of 2016. The electronic databases searched included MEDLINE (PubMed), and ScienceDirect (as of January 5, 2016). The key words and terms searched included: (“Pancreas Divisum” OR “Pancreatic Divisum”) AND (“Endoscopic therapy” OR “Endotherapy” OR “Endoscopy” OR “ERCP”). The search was performed within the title, abstract, and key words. The references of relevant articles were reviewed and additional abstracts were added. The search strategy is detailed in Fig. 1.

Study selection and inclusion criteria

Two reviewers (LM & BA) independently searched the literature and identified studies for inclusion. Disagreements were resolved by consensus between the two authors and discussion with a senior author (HM) when necessary. Exclusion criteria were: article published in language other than English, abstract form only with no full text available, case series with total number of patients less than or equal to 5, case reports, review articles, and series that including a pediatric patient population or were not relevant to the research question. Studies focusing on a subset of PDiv patients, such as those relating to santoerinecle, were excluded [7]. Studies with unconventional interventions, such as botulinum toxin injection [8], were also excluded from the review as they did not fall into the three standard categories of endotherapy. Studies with both complete and incomplete divisum patients were included.

Data extraction and quality assessment

Data included the following pre-defined characteristics and variables: first author last name, year of publication, study design, patient demographics (mean age, sex), number of patients with each clinical presentation (RAP versus CP versus PP), number of patients who only received endotherapy, type of endotherapy used, follow-up duration, definition of successful endotherapy, total success rates, success rates for each clinical presentation, rates of adverse events and rates of pancreatitis following endoscopic retrograde cholangiopancreatography (ERCP). Since all studies identified were case series, the quality of each study was assessed using the checklist developed by Moga et al (Institute of Health Economics, Alberta, Canada) to assess the quality of case series (Table 2A) [9]. The number of points scored by each study can be seen in Table 2B. Studies scoring >14 points are considered to be of “good” quality.

Heterogeneity testing and publication bias assessment

Assessment of heterogeneity was performed by calculating Cochran’s Q statistic, $I^2$ (estimates the between-study variance) and $F$ (quantifies the degree of heterogeneity) with P values <0.1 considered statistically significant [10,11]. Publication bias was assessed using a funnel plot. Heterogeneity was
assessed for each individual outcome (endotherapy success rate, pancreatitis rate) and subgroup (Total, RAP, CP, PP).

Outcomes measured

1. Author-defined overall success rates of endotherapy, as well as success rates for each individual clinical presentation: RAP, CP, PP
2. Overall reported post-ERCP pancreatitis rates
3. Patient population-related and study design-related potential predictors of successful endotherapy

Data synthesis and statistical analysis

Only the patients for whom final outcomes were reported were included in the analysis. Patients who were lost to follow up were not included. Separate pooled success rates for each of the clinical presentations (RAP, CP, PP) were calculated by analyzing 3 different subgroups. Post-ERCP pancreatitis rates were pooled and analyzed for the studies that reported them. Variables of interest were treated as continuous variables with means and variations. A random effects model was used to calculate pooled effects for each outcome and subgroup [12]. Finally, we performed a meta-regression analysis in an attempt to identify predictors of successful endotherapy. The regression model included the following covariates: year of publication, sex, age, mean study follow up in months and type of endoscopic therapy used. We divided the endotherapy into 4 main types: minor papilla sphincterotomy and stent, minor papilla sphincteroplasty and stent, stenting of the minor papilla only (stent only), and combination therapy (combination). The minor papilla sphincterotomy and stenting group was used the reference group, as this is currently the most commonly employed therapy. Several studies reported median ages and/or median durations of follow up; for these studies, means and variances were recalculated using a formula previously described by Hozo et al [13] and mean values were included in the analysis. Six studies [14-19] were not included in the meta-regression because they lacked data for some covariates, bringing the number of studies analyzed to 17. Statistical analyses were performed using Comprehensive Meta-Analysis (CMA) software, version 3.3.070, 2014 (Biostat, Englewood, NJ 07631, USA).

Results

Descriptive assessment of included studies

Our initial literature search of online databases yielded 503 articles. After removal of duplicates, 282 articles were selected and further reviewed; 99 original articles were added from cross-referencing, bringing the total number of articles reviewed to 381. Of these, 23 studies were selected for final inclusion after application of the exclusion criteria. The search strategy and study selection process is detailed in Supplemental Fig. 1. Studies included were published during the period from 1988 to 2014. Most studies were retrospective case series conducted at a single center; one study was performed at two centers [15]. Only 5 of the 23 studies were prospective [15,20-23] and only 2 of these included a comparative arm [21,22]. Three were performed in Europe [22,24,25], 3 in Asia [15,26,27], 1 in Australia [28], and the remainder in the United States. Twenty-one of the 23 studies reported adverse events rates. Seventeen of the 23 reported male: female ratios, and 45.4% of the patients in those studies were male. Twenty-one studies reported mean or median follow up and, in the same fashion, an average follow up of 36.6 months was calculated. The study characteristics are outlined in Table 1.

Qualitative assessment of included studies

Five of the 23 studies [16,18,27,29,30] had 13/18 “yes” responses and 2 of 23 [19,23] had 11/18 “yes” responses. The results of the validity testing can be viewed in Table 2B.

Publication bias

Publication bias was assessed by generating funnel plots. Visual interpretation of the plot for standard error (Fig. 2) shows that the studies are distributed symmetrically around the combined effect size, with the exception of a few smaller studies that appear to have larger than average effect sizes (rates of successful endotherapy in this case); this probably indicates the presence of publication bias.

Heterogeneity

Assessment of heterogeneity was performed by calculating Cochran’s Q statistic, $r^2$ and $P$. Substantial heterogeneity was detected ($P \geq 50\%$) under the fixed effects model, so we
Table 1: Study characteristics

| Author (Year) | Total patients | Patients treated with endotherapy | Endotherapy modality | Age | Male (%) | Successful endotherapy number | Successful endotherapy (%) | Mean F/U (months) | Pancreatitis rate (%) |
|---------------|----------------|-----------------------------------|----------------------|-----|----------|-------------------------------|---------------------------|---------------------|----------------------|
| Yamamoto (2014) [27] | 83 | 16 | Sphincteroplasty and stent | 53.6 | 75 | 13 | 81.2 | 54.8 | 1 |
| Mariani (2014) [22] | 36 | 19 | MPS and stent | 55.6 | 79 | 14 | 73.7 | 54.0 | 7 |
| Rustagi (2013) [18] | 45 | 33 | Combination | 50 | - | 25 | 75.8 | - | 7 |
| Bhasin (2013) [26] | 48 | 47 | MPS and stent | 32.6 | 66 | 45 | 95.7 | 77.7 | 1 |
| Borak (2009) [18] | 145 | 113 | Combination | 48.6 | 29 | 70 | 61.9 | 54.1 | 12 |
| Kwan (2008) [28] | 21 | 21 | MPS and stent | 38.2 | 67 | 13 | 61.9 | 36.7 | 2 |
| Chacko (2008) [35] | 57 | 46 | MPS and stent | 45.7 | 33 | 26 | 56.5 | 22.8 | 11 |
| Vitale (2007) [33] | 32 | 24 | MPS and stent | 43.8 | 29 | 13 | 54.2 | 59.6 | - |
| Attwell (2006) [26] | 184 | 184 | MPS and stent | 46.6 | 30 | 133 | 72.3 | 63.0 | 12 |
| Gerke (2004) [40] | 89 | 53 | MPS and stent | 50.5 | 36 | 32 | 60.4 | 40.7 | 10 |
| Heyries (2002) [25] | 24 | 24 | Combination | 44.3 | 67 | 22 | 91.7 | 52.3 | 3 |
| Kim (2001) [15] | 56 | 23 | MPS and stent | 54 | - | 15 | 65.2 | 17.0 | 2 |
| Ertan (2000) [20] | 25 | 25 | Sphincteroplasty and stent | 41.5 | 60 | 19 | 76.0 | 24.0 | 0 |
| Boerma (2000) [24] | 16 | 16 | Combination | 40.4 | 50 | 5 | 31.3 | 57.4 | 1 |
| Jacob (1999) [14] | 32 | 18 | Combination | 42 | - | 11 | 61.1 | 15.5 | 1 |
| Cohen (1995) [31] | 20 | 18 | MPS and stent | 43.3 | 33 | 13 | 72.2 | 22.0 | 6 |
| Kozarek (1995) [16] | 39 | 39 | Combination | - | 24 | 18 | 46.2 | 26.0 | 4 |
| Coleman (1994) [29] | 34 | 34 | MPS and stent | 46 | 29 | 22 | 64.7 | 23.0 | 5 |
| Lehman (1993) [30] | 51 | 51 | MPS and stent | 44.5 | 25 | 22 | 43.1 | 20.4 | - |
| Lans (1992) [21] | 10 | 10 | Stent only | 49.7 | 50 | 9 | 90.0 | 28.6 | 1 |
| Siegel (1990) [23] | 31 | 31 | Stent only | 35 | 16 | 26 | 83.9 | 24.0 | - |
| Satterfield (1988) [19] | 82 | 10 | Sphincteroplasty and stent | 48.5 | - | 6 | 60.0 | 18.2 | - |
| McCarthy (1988) [17] | 35 | 19 | Stent only | - | 18 | 17 | 89.5 | 14.0 | 5 |

RAP, recurrent acute pancreatitis; CP, chronic pancreatitis; PP, pancreatic-type pain; MPS, minor papilla sphincterotomy
Table 2A Quality assessment tool used [9]

| Criterion:                                                                 | 1   | 2   | 3   | 4   | 5   | 6   | 7   | 8   | 9   | 10  | 11  | 12  | 13  | 14  | 15  | 16  | 17  | 18  | Sum |
|---------------------------------------------------------------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Is the hypothesis/aim/objective of the study stated in the abstract, introduction, or methods section? | Y   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     | 13  |
| Are the characteristics of the patients included in the study clearly described? | Y   | Y   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Were the case series collected in more than one center? | Y   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Are the eligibility criteria (inclusion and exclusion criteria) explicit and appropriate? | Y   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Were patients recruited consecutively? | Y   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Did patients enter the study at a similar point in the disease? | Y   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Did the authors describe the intervention? | Y   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| In addition to intervention, did the patients receive any co-intervention? | Y   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Are outcomes (primary, secondary) clearly defined in the introduction or methodology section? | Y   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Did the authors use accurate (standard, valid, reliable) objective methods to measure the outcomes? | Y   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Were outcomes assessed before and after intervention? | Y   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Were the statistical tests used to assess the primary outcomes appropriate? | Y   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Was the length of follow up clearly described/reported? | Y   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Was the loss to follow up reported? | Y   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Does the study provide estimates of the random variability in the data for the primary outcomes (e.g. standard error, standard deviation, confidence intervals)? | Y   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Are adverse events reported? | Y   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Are the conclusions of the study supported by results? | Y   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Are both competing interest and source of support for the study reported? | Y   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |

Table 2B Quality assessment of studies

| Study                   | 1   | 2   | 3   | 4   | 5   | 6   | 7   | 8   | 9   | 10  | 11  | 12  | 13  | 14  | 15  | 16  | 17  | 18  | Sum |
|-------------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Yamamoto [27]           | Y   | Y   | N   | N   | N   | N   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | N   | Y   | Y   | Y   | 13  |
| Mariani [22]            | Y   | Y   | N   | Y   | Y   | N   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | N   | Y   | Y   | 15  |
| Rustagi [18]            | Y   | Y   | N   | Y   | N   | N   | Y   | Y   | N   | Y   | N   | N   | Y   | Y   | Y   | Y   | Y   | Y   | 11  |
| Bhasin [26]             | Y   | Y   | N   | Y   | N   | N   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | 15  |
| Borak [34]              | Y   | Y   | N   | Y   | N   | N   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | 14  |
| Kwan [28]               | Y   | Y   | N   | Y   | N   | N   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | 14  |
| Chacko [35]             | Y   | Y   | N   | Y   | N   | N   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | 16  |
| Vitale [33]             | Y   | Y   | N   | Y   | N   | N   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | 14  |
| Attwell [32]            | Y   | Y   | N   | Y   | N   | N   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | 15  |
| Gerke [40]              | Y   | Y   | N   | Y   | N   | N   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | 14  |
| Heyries [25]            | Y   | Y   | N   | Y   | N   | N   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | 14  |
| Kim [15]                | Y   | Y   | Y   | Y   | N   | N   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | 15  |
| Ertan [20]              | Y   | Y   | N   | Y   | N   | N   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | 15  |
| Boerma [24]             | Y   | Y   | N   | Y   | N   | N   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | 14  |
| Cohen [31]              | Y   | Y   | N   | Y   | N   | N   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | 14  |
| Coleman [29]            | Y   | Y   | N   | Y   | N   | N   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | 13  |
| Lehman [30]             | Y   | Y   | N   | Y   | N   | N   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | 13  |
| Siegel [23]             | Y   | Y   | N   | Y   | N   | N   | Y   | Y   | Y   | Y   | N   | N   | Y   | Y   | Y   | Y   | Y   | 11  |
| Satterfield [19]        | Y   | Y   | N   | Y   | N   | N   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | 13  |
| McCarthy [17]           | Y   | Y   | N   | Y   | N   | N   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | 14  |
| Jacob [14]              | Y   | Y   | N   | Y   | N   | N   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | 14  |
| Kozarek [16]            | Y   | Y   | N   | Y   | N   | N   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | 13  |
| Lans [21]               | Y   | Y   | N   | Y   | Y   | N   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | Y   | 14  |
concluded that the assumptions of the fixed effects model had been violated and used the random effects model to calculate pooled effects for each outcome and subgroup [12]. The results of heterogeneity testing for each measured outcome are noted in Table 1.

Primary outcome: endoscopic therapy success rates

In the 23 studies included in the analysis, a total of 874 patients received endoscopic therapy for PDiv. Endotherapy was deemed “successful” by the investigators in 589 of those patients. The pooled success rate of endotherapy was calculated at 67.5% (95% confidence interval [CI] 0.610-0.734; 2-sided P=0.0001). A forest plot of pooled endotherapy success rates is shown in Fig. 3. We analyzed the pooled endotherapy success rates of 3 patient subgroups: RAP, CP and PP. In total, 401 patients from 17 studies were reported to present with RAP and endotherapy was successful, as per author definition, in 289 of these patients. The pooled success rate of endotherapy in patients with RAP was 76% (95%CI 0.712-0.803; 2-sided P=0.0001). Patients presenting with CP and PP did not benefit from endotherapy to the same extent. In 283 patients with CP, reported in 14 studies, endotherapy was successful in 164. The pooled success rate in CP patients was 52.4% (95%CI 0.406-0.640; 2-sided P=0.692) indicating an equivocal effect in this subset of patients. Fewer patients were treated with PP; of 131 patients PP from 10 studies, endotherapy was successful in 64. The pooled success rate in PP patients was 48% (95%CI 0.371-0.590; 2-sided P=0.723). Fig. 4 shows a forest plot of endotherapy success rates in patients with RAP, CP or PP. Of 23 studies, 19 reported rates of post-ERCP pancreatitis. The pooled rate of post-ERCP pancreatitis was calculated at 10.1% (95%CI 0.084-0.124; 2-sided P=0.0001).

Predictors of successful endoscopic therapy

Seventeen studies that had complete data for all the covariates assessed were included in a meta-regression analysis. The optimal regression fixed effects model included the following covariates: percentage of male patients, mean follow up in months, and dorsal pancreatic duct stenting only. This model explained 16% of the between-study variance with an $R^2$ value of 0.16, P-value= 0.059.

Dorsal duct stenting only (coefficient=1.66, standard error [SE]=0.47, 2 sided P=0.004) and longer duration of follow up (coefficient=0.017, SE=0.005, 2 sided P=0.012) were the only factors associated with better endotherapy success rates. There was a trend for higher success rate among male patients that did not reach statistical significance (2 sided P=0.074).

Discussion

The primary objective of our meta-analysis was to assess the efficacy of endoscopic therapy in the management of PDiv and obtain a more accurate estimate of the effect size. We found that endoscopic therapy was reported to be successful in PDiv with a pooled efficacy rate of 67.5%. Although this rate is likely to be more accurate than those reported in individual studies, it is far from being conclusive in view of the suboptimal study design, lack of a uniform outcome definition, and variable...
follow-up durations among the studies analyzed. The definition of "successful therapy" varied quite significantly among studies. Some of the definitions used were: no recurrence of pancreatitis episodes after therapy [22,27], decreased number of pancreatitis episodes [28], improvement in patient-reported pain [15,21,23,24,29,31] or no further pain reported [14,24,27], decreased use of analgesics [25], improvement in patient-reported quality of life [26], no need for further therapy [32], no need for surgical therapy [33], decrease in the number of hospitalizations [18,30], decreased emergency room visits [17], and number of therapeutic ERCP sessions the patients required [34]. Several authors used a combination of these definitions [16,17,20,26,34,35]. These variable definitions of success make it hard to generalize conclusions.

Not all authors provided precise definitions of RAP, CP or PP in the studies. However, RAP was mostly defined as at least 2 prior documented episodes of pancreatitis without calcification of the pancreas; recurrent episodes of abdominal pain compatible with a pancreatic origin with an increase in amylase or lipase levels within a year. CP was defined as pancreatic pain coupled with typical radiographic or pancreatographic findings. The maximal therapeutic benefit was observed in patients who presented with RAP, with a pooled efficacy rate of 76%. The therapeutic effect was equivocal in patients with CP and PP. The reason for this difference in response to endoscopic therapy is not fully understood. Some authors postulate that genetic factors predispose people with pancreatic disease to intermittent obstruction (leading to pancreatitis and sequelae [36,37]), which is alleviated by reducing transpapillary pressure with endotherapy in regard to RAP. In contrast, in CP and PP patients it has been suggested that the duct may have sustained irreversible damage that does not make it amenable to endoscopic drainage [18]. Others have postulated that the presence of PDiv is merely an incidental finding in this group.

**Figure 4** Forest plot of endotherapy success by clinical presentation

**RAP**, recurrent acute pancreatitis; **CP**, chronic pancreatitis; **PP**, pancreatic-type pain PP.
of patients [2] and not the primary etiology behind their symptoms; thus, performing endotherapy would not improve their condition. The post-ERCP pancreatitis pooled rate was 10% (95% CI 0.084-0.124; P=0.0001). Although reported rates vary in the literature, for comparison, in a large analysis of 21 prospective studies, involving 16,855 patients, ERCP-attributable complications occurred in 6.85% (95% CI 6.46-7.24%) of the procedures with a pancreatitis rate of 3.47% (95% CI 3.19-3.75%) [38]. In our analysis, the incidence of post-ERCP pancreatitis in patients with pancreatic disease undergoing endotherapy was higher compared to other indications, suggesting that efforts to minimize adverse outcomes should be considered. The exact reason for this is unclear, but the more interventional nature of PDiv endotherapy compared to standard diagnostic ERCP may have contributed to this observation. In addition, the varied types of endotherapy chronology, and other variables that were not reported or recorded in studies (such as the use of rectal indomethacin) make it difficult to extract conclusions.

We sought to identify potential predictors of successful endoscopic therapy through multivariate analysis. Other than clinical presentation, two variables were noted to be associated with improved outcomes: dorsal duct stenting only and longer follow-up duration. In addition, male patients tended to have better response rates, although the difference did not reach statistical significance. It is likely that dorsal duct stenting may decrease the risk of post-ERCP pancreatitis [41] and potentially allows for more effective drainage in some patients. However, it is important to note that only 2 out of the 17 studies in the regression analysis employed dorsal duct stenting only, without a sphincteroplasty or sphincterotomy, as the main endotherapy. Furthermore, those studies were some of the earlier ones, done in 1990 and 1992. The reason why better outcomes were associated with a longer follow-up duration is unclear. Potential explanations include the elimination of the placebo effect with longer duration, more endotherapy sessions and frequent contact with medical providers. The major limitation of the current analysis is the absence of high-quality, well-designed studies. The studies available are by and large single-center uncontrolled retrospective case series with a high risk of selection and reporting bias. In addition, the definition of success varied widely and lacked validity and reliability in a significant number of studies; subjective measures, such as patient-rated improvement in pain, were frequently employed to determine success [39]. All of the above factors explain the substantial heterogeneity observed within and across studies. It is important to note that we only included fully published studies in the English language and funnel plots indicated the presence of at least potential publication bias (mostly studies with a positive effect).

In conclusion, endoscopic therapy for PDiv is probably effective in a subset of patients who present with RAP. The benefit is less clear in patients with CP and/or PP. The post-ERCP pancreatitis rate is higher than average and should be quoted at 10%. The overall quality of the available data is poor, as a result of suboptimal study design and significant heterogeneity. High-quality prospective randomized trials, with standardized, objective, valid and reliable outcome measures are needed to establish the exact role of endoscopic therapy in the management of PDiv.

**References**

1. Liao Z, Gao R, Wang W, et al. A systematic review on endoscopic detection rate, endotherapy, and surgery for pancreas divisum. *Endoscopy* 2009;41:439-444.
2. DiMagno MJ, Wamsteker EJ. Pancreas divisum. *Carr Gastroenterol Rep* 2011;13:150-156.
3. Delhaye M, Matos C, Arvanitakis M, Deviere J. Pancreatic ductal system obstruction and acute recurrent pancreatitis. *World J Gastroenterol* 2008;14:1027-1033.
4. Klein SD, Affronti JP. Pancreas divisum, an evidence-based review: part I, pathophysiology. *Gastrointest Endosc* 2004;60:419-425.
5. Khalid A, Slivka A. Approach to idiopathic recurrent pancreatitis. *Gastrointest Endosc Clin N Am* 2003;13:695-716.
6. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med* 2015;162:777-784.
7. Lutzak GD, Gluck M, Ross AS, Kozarek RA. Endoscopic minor papilla sphincterotomy in patients with santoriniceles reduces pain and improves quality of life. *Dis Dig Sci* 2013;58:2075-2081.
8. Wehrmann T, Schmitt T, Seifert H. Endoscopic botulinum toxin injection into the minor papilla for treatment of idiopathic recurrent pancreatitis in patients with pancreas divisum. *Gastrointest Endosc*
outcome of endoscopic therapy in patients with symptomatic chronic pancreatitis associated with pancreas divisum. JOP 2013;14:50-56.
27. Yamamoto N, Isayama H, Sasahira N, et al. Endoscopic minor papilla balloon dilation for the treatment of symptomatic pancreas divisum. Pancreas 2014;43:927-930.
28. Kwan V, Loh SM, Walsh PR, Williams SJ, Bourke MJ. Minor papilla sphincterotomy for pancreatitis due to pancreas divisum. ANZ J Surg 2008;78:257-261.
29. Coleman SD, Eisen GM, Troughton AB, Cotton PB. Endoscopic treatment in pancreas divisum. Am J Gastroenterol 1994;89:1152-1155.
30. Lehman GA, Sherman S, Nisi R, Hawes RH. Pancreas divisum: results of minor papilla sphincterotomy. Gastrointest Endosc 1993;39:1-8.
31. Cohen SA, Rutkovsky FD, Siegel JH, Kasmin FE. Endoscopic stenting and sphincterotomy of the minor papilla in symptomatic pancreas divisum: results and complications. Diagn Ther Endosc 1995;1:131-139.
32. Attwell A, Borak G, Hawes R, Cotton P, Romagnuolo J. Endoscopic pancreatic sphincterotomy for pancreas divisum by using a needle-knife or standard pull-type technique: safety and reintervention rates. Gastrointest Endosc 2006;64:705-711.
33. Vitale GC, Vitale M, Vitale DS, Binford JC, Hill B. Long-term follow-up of endoscopic stenting in patients with chronic pancreatitis secondary to pancreas divisum. Surg Endosc 2007;21:2199-2202.
34. Borak GD, Romagnuolo J, Alsolaiman M, Holt EW, Cotton PB. Long-term clinical outcomes after endoscopic minor papilla therapy in symptomatic patients with pancreas divisum. Pancreas 2009;38:903-906.
35. Chacko LN, Chen YK, Shah RJ. Clinical outcomes and nonendoscopic interventions after minor papilla endotherapy in patients with symptomatic pancreas divisum. Gastrointest Endosc 2008;68:667-673.
36. Staritz M, Meyer zum Büschenfelde KH. Elevated pressure in the dorsal part of pancreas divisum: the cause of chronic pancreatitis? Pancreas 1988;3:108-110.
37. Muzzaffar AR, Moyer MS, Dobbins J, Cahow CE, Gryboski JD, Shneider BL. Pancreas divisum in a family with hereditary pancreatitis. J Clin Gastroenterol 1996;22:16-20.
38. Andriulli A, Loperfido S, Napolitano G, et al. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol 2007;102:1781-1788.
39. Moustgaard H, Bello S, Miller FG, Hróbjartsson A. Subjective and objective outcomes in randomized clinical trials: definitions differed in methods publications and were often absent from trial reports. J Clin Epidemiol 2014;67:1327-1334.
40. Gerke H, Byrne MF, Stiffler HL, et al. Outcome of endoscopic minor papillotomy in patients with symptomatic pancreas divisum. JOP 2004;5:122-131.
41. Singh P, Das A, Isenberg G, et al. Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials. Gastrointest Endosc 2004;60:544-550.